Terms and Conditions

World Pharma News Portal (the "Portal") is a web based news platform maintained by DAVID eHealth & Pharma UG ("Administrator", "Editor" "we," or “us”).

Terms of Use

We are not responsible for published news release, announce and any other related multimedia content (“News Content") in any way, including without limitation, any copyright, trademark, publicity, privacy, contract or other rights clearance, or the accuracy, timeliness, integrity, quality, safety, appropriateness or other aspect of any information or other content contained therein. You are solely responsible for verifying the accuracy and completeness of News Content, and for determining if any permissions are necessary to use the News Content, and, if so, for securing those permissions prior to your use of the New Content. If you choose to rely on or otherwise use News Content in any way you do so solely at your own risk and without any representation or warranty whatsoever from us.

Disclaimer Notice

The Portal includes pharmaceutical related information, news and resources on which it is operated or contained, which is made available by the Project Administrator and Portal Partners, Contributors. Our goal is to keep this information timely and accurate. If errors are brought to our attention, we will try to correct them.

However we accepts no responsibility or liability whatsoever with regard to the material on this site. This material is:

  • Information of a general nature only which is not intended to address the specific circumstances of any particular individual or entity
  • Not necessarily comprehensive, complete, accurate or up to date
  • Sometimes linked to external sites over which we have no control and for which we assumes no responsibility

Please note that it cannot be guaranteed that a document available online exactly reproduces an officially adopted text. It is our goal to minimise disruption caused by technical errors. However some data or information on Portal may have been created or structured in files or formats that are not error-free and we cannot guarantee that our service will not be interrupted or otherwise affected by such problems. We accepts no responsibility with regard to such problems, or the consequences thereof, incurred as a result of using this site or any linked external sites.

Copyright Notice

This World Wide Web site includes information, and the software and media on which it is operated or contained, individually and collectively known as the "Information" which include RSS, Web Links and News made available by us.

The Information has been supplied by us and portal Partners, Contributors, and/or by companies or organisations involved in Pharmaceutical business, research and development activities (the "Information Suppliers"). All title and intellectual property rights, including, but not limited to, trademarks, copyrights in and to the Information, and any copies thereof in whatever form, are owned by the Information Suppliers, and/or by the Portal Administrator, and/or by other parties, and are protected by the applicable laws. Any trademarks or names being used are for editorial purposes only, and to the benefit of the trademark owner, with no intention of infringing upon that trademark.

Except where otherwise noted, all site contents are:
© World Pharma News.

Reproduction is authorised, provided its source "World Pharma News" or "www.worldpharmanews.com" (with web link to http://www.worldpharmanews.com) is acknowledged.

Advertising

On the Portal, the editorial content and process are always clearly separated from advertising. Advertising spaces such as banners (images or texts) are clearly marked or separated. Likewise, any content provided by an advertising sponsor is clearly marked as such, and is physically separated from editorial content. We are also selective in the advertising we accept. Our main advertising policies are as follows:
  • We will clearly distinguish advertising from Pharmaceutical and Health information content, using identifying words, design, or placement. We design our web sites to avoid confusion between advertising and healthcare information content.
  • Under no circumstances acceptance of an advertisement will be considered a Portal endorsement of the product(s) or the company advertised.

Please note that Portal Administrator will consider, within appropriate editorial context, all critics related to the advertisements or our Advertising Policy.

Personal Data Protection Policy

We are committed to user privacy. To better protect your privacy, we provide this notice explaining our on-line information practices and the choices you can make about the way your information is collected and used by us.

You can browse freely through most of the Portal without giving any information about yourself. However, in some cases, personal information may be required in order to enable us to provide the e-services you request. Please note that we collect no personal information about you when you visit our Web site unless you choose to provide that information to us.

Data Protection by Third-party Sites

Some Portal Web pages contain links to other sites whose information practices may be different to those of World Pharma News. We encourage you to read the privacy statements on other Web sites you visit, as we have no control over information that is submitted to, or collected by, these third parties.

Log files

Log files allow us to record visitors' use of the site. We puts together log file information from all our visitors, which we use to improve our understanding of user needs and patterns of behavior, and to make improvements to the layout of the site and to the information in it, based on the way that visitors move around it. Log files do not contain any personal information about you. We automatically collect non-personal information such as:
  • The type and version of the operating system of your computer
  • The type and version of the browser used to access our Portal.
  • The Internet domain.
  • The IP address from which you access our Portal.
  • The date and time you access our Portal.
  • The pages you visit.
  • If you linked to our Portal from another Web site, the address of that Web site.

If this Privacy Notice changes in any way, we will place an updated version on this page. Regularly reviewing this page ensures that you are always aware of what information we collect, how we use it and under what circumstances, if any, we will share it with other parties.

In case of further questions, comments or suggestions regarding above Privacy Notice please don't hesitate to contact us.

Most Popular Now

Johnson & Johnson announces European Commissio…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Pur...

BioNTech and Pfizer initiate rolling submission to…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lea...

Vir Biotechnology and GSK announce global expansio…

Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Eff...

Johnson & Johnson initiates pivotal global Pha…

Johnson & Johnson (NYSE: JNJ) (the Company) announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, J...

COVID-19 Long-Acting AntiBody (LAAB) combination A…

AstraZeneca's long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside th...

COVID-19 vaccine AZD1222 clinical trial resumed in…

The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). ...

Adequate levels of vitamin D reduces complications…

Hospitalized COVID-19 patients who were vitamin D sufficient, with a blood level of 25-hydroxyvitamin D of at least 30 ng/mL (a measure of vitamin D status), had a signif...

Gilead Sciences signs joint procurement agreement …

Gilead Sciences (Nasdaq: GILD) and the European Commission signed a joint procurement agreement (JPA) that will enable rapid and equitable access to Veklury® (remdesivir)...

Protective antibodies persist for months in surviv…

People who survive serious COVID-19 infections have long-lasting immune responses against the virus, according to a new study led by researchers at Massachusetts General ...

Potential COVID-19 vaccines not affected by domina…

Vaccines currently being developed for COVID-19 should not be affected by recent mutations in the virus, according to a new study involving a University of York virologis...

Regeneron's REGN-COV2 antibody cocktail reduced vi…

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cockta...

Popular COVID-19 conspiracies linked to vaccine 'h…

A new study of beliefs and attitudes toward COVID-19 in five different countries - UK, US, Ireland, Mexico and Spain - has identified how much traction some prominent con...